Can-Fite BioPharma Ltd. - American Depositary Receipt

Can-Fite BioPharma Ltd. - American Depositary Receipt represents shares of a biopharmaceutical company focused on developing small-molecule drugs for the treatment of autoimmune, inflammatory, and liver diseases. As an American Depositary Receipt, it allows U.S. investors to invest in Can-Fite BioPharma, which is originally based in Israel, without the complexities of cross-border transactions. Can-Fite applies its expertise in drug development to target specific inflammatory pathways and diseases such as psoriasis, rheumatoid arthritis, and advanced liver conditions. The company is at the forefront of novel treatments and therapeutics, leveraging its proprietary drug technologies to address unmet medical needs. American Depositary Receipts like Can-Fite's play a pivotal role in cross-listing international companies on U.S. exchanges, thereby expanding investor reach and increasing market liquidity. This accessibility helps investors diversify their portfolios with a wide range of global biopharmaceutical assets, capitalizing on cutting-edge research and development in specialized medical fields.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Motti Farbstein

Employees

5

Headquarters

Ramat Gan, Israel

Website

www.canfite.com